Zynerba Pharma Balance Sheet - Annual (NASDAQ:ZYNE)

Add to My Stocks
$11.57 $0.82 (6.62%) ZYNE stock closing price Jun 22, 2018 (Closing)

A thorough fundamental analysis involves using data from Zynerba Pharma balance sheet, apart from other financial statements, to value the business. Financial strength can be guaged by performing Zynerba Pharma stock analysis and by analyzing the balance sheet. Annual results are typically accompanied with the company releasing financial statements. The Zynerba Pharma balance sheet for 2017 shows total assets of $69.05M. The company has a asset turnover ratio of 0. Also see: Zynerba Pharma revenue and Zynerba Pharma operating cash flow for the same year.

View latest 10 year balance sheet data to check Zynerba Pharma financial performance.
show more
Fiscal year is Jan - Dec20172016201520142013
Cash62.51M30.96M41.51M9.33M-
Marketable Securities-----
Receivables3.98M3.61M---
Inventory-----
Raw Materials-----
Work In Progress-----
Finished Goods-----
Notes Receivable-----
Other Current Assets1.73M1.83M1.9M2.26M-
Total Current Assets
68.22M36.41M43.41M11.59M-
Property Plant & Equipment-----
Accumulated Depreciation-----
Net Property Plant & Equipment
-----
Investment & Advances-----
Other Non-Current Assets-----
Deferred Charges-----
Intangibles-----
Deposits & Other Assets----1.12M
Total Assets
69.05M36.55M43.64M11.61M1.86M
Notes Payable-----
Accounts Payable3.35M1.84M---
Current Portion Long-Term Debt-----
Current Portion Capital Leases-----
Accrued Expenses3.91M4.28M2.27M1.71M-
Income Taxes Payable-----
Other Current Liabilities---1.12M1.07M
Total Current Liabilities
7.44M6.96M3.93M3.14M1.56M
Mortgages-----
Deferred Taxes/Income----1.12M
Convertible Debt-----
Long-Term Debt-----
Non-Current Capital Leases-----
Other Long-Term Liabilities-----
Total Liabilities
8.1M6.96M3.93M3.14M3.05M
Minority Interest-----
Preferred Stock---16.52M3.16M
Common Stock Net-----
Capital Surplus138.91M75.54M62.27M1.97M-
Retained Earnings-77.98M-45.96M-22.58M-10.02M-4.35M
Treasury Stock-----
Other Liabilities-----
Shareholders Equity60.94M29.58M39.7M8.47M-1.19M
Total Liabilities & Shareholders Equity69.05M36.55M43.64M11.61M1.86M
All figures in USD. M: Millions of USD, B: Billions of USD.

Apart from balance sheet items, an investor would do well to keep track of the Zynerba Pharma stock price by looking at Zynerba Pharma historical stock prices. One can compare PE with industry average by looking at the Zynerba Pharma PE ratio chart. The common balance sheet items are:

  • Assets: An asset is a resource that a corporation like Zynerba Pharma owns and has monetary significance. ZYNE assets grew from $36.55M in 2016 to $69.05M in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Zynerba Pharma is $8.1M. Shareholders' equity comes under liabilities as it is money the company owes the holders of ZYNE stock.

Zynerba Pharma Balance Sheet - Key Ratios

Current ratio
6.51
Debt to equity ratio
0
Asset turnover ratio
0
Receivables turnover
0